The study indicated that the JAK2/STAT3 signaling pathway may be involved in the pathogenesis of the demyelinating subtype of GBS, and AG490 treatment might potentially benefit GBS patients. The gene discussed is JAK2; the disease is Guillain-Barre syndrome.